Szczepionka PEP-CMV ukierunkowana na antygen CMV w leczeniu nowo zdiagnozowanego pediatrycznego HGG i DIPG oraz nawracającego rdzeniaka zarodkowego
Badanie fazy 2 nowej szczepionki peptydowej (PEP-CMV) ukierunkowanej na antygen CMV dla nowo zdiagnozowanego dziecięcego glejaka wysokiego stopnia i rozlanego wewnętrznego glejaka mostu i nawracającego rdzeniaka zarodkowego
This study will address the question of whether targeting CMV antigens with PEP-CMV can serve as a novel immunotherapeutic approach in pediatric patients with newly-diagnosed high-grade glioma (HGG) or diffuse intrinsic pontine glioma (DIPG) as well as recurrent medulloblastoma (MB).
PEP-CMV is a vaccine mixture of a peptide referred to as Component A. Component A is a synthetic long peptide (SLP) of 26 amino acid residues from human pp65. The SLPs encode multiple potential class I, class II, and antibody epitopes across several haplotypes. Component A will be administered as a stable water:oil emulsion in Montanide ISA 51.
Funding Source - FDA OOPD
Przegląd badań
Status
Status
Warunki
Warunki
Interwencja / Leczenie
Interwencja / Leczenie
Szczegółowy opis
This phase II clinical trial will have 3 strata in order to assess the efficacy of a highly immunogenic CMV-directed peptide vaccines in children with (1) recurrent medulloblastoma (rMB), (2) newly-diagnosed high-grade gliomas (HGG) and (3) newly-diagnosed diffuse intrinsic pontine glioma (DIPG). Each stratum will run independently with a different endpoint and statistical design.
Within each stratum, the populations that may be used for analysis are defined as:
- Safety Analysis: Patients who receive at least 1 dose of the treatment will be used for safety analyses.
- Efficacy Analysis: Patients who receive at least 1 dose of the treatment will be used for efficacy analyses.
Stratum I: Patients with recurrent medulloblastoma with measurable disease (see eligibility) can be enrolled at any point following recurrence regardless of any prior therapy. For the purpose of this study, recurrence will be defined as a new lesion confirmed by biopsy or resection, positive cerebrospinal fluid (CSF) cytology, or recurrent/progressive tumor on MRI.
Strata II [CLOSED on 19Aug2026] and III: Patients with newly-diagnosed high-grade glioma [CLOSED on 19Aug2026] or DIPG may be enrolled any time within 42 days after completing radiation.
Cycle 1 (Induction cycle) is 77±2 days. Patients will receive one course of temozolomide 200 mg/m2/day x 5 days on Days 1-5 of cycle 1 and receive PEP-CMV vaccine intradermally at dose level 1 (250 μg/m2 ) on Days 21, 35 ±2 days, and 49 ±2 days. After the induction cycle which is 77 ± 2 days, each subsequent cycle is 28 days. Starting in cycle 2, PEP-CMV vaccine is administered intradermally every 28 days on day 1 of each course. Patient can continue to receive PEP-CMV every 28 days for a total of 24 cycles.
Patients will receive a tetanus (Td) booster (Td 5 flocculation units, Lf) at the time of enrollment. Immunotherapy begins with a Td pre-conditioning vaccine (Td 1 Lf, in 0.4 mL of saline) delivered i.d. at the RIGHT groin site of the vaccine injection 6-24 hours prior to the first vaccine on day 21.
The PEP-CMV vaccine will be administered as follows: 250 µg/m2 (up to a maximum of 500 µg) of Component A mixed with Montanide ISA-51 (1:1 volume ratio) intradermally administered half in the RIGHT groin and half in the LEFT groin.
Typ studiów
Typ studiów
Zapisy (Szacowany)
Zapisy
Faza
Faza
- Faza 2
Kontakty i lokalizacje
Kontakt w sprawie studiów
Kontakt w sprawie studiów
- Nazwa: Kelsey H Troyer, PhD
- Numer telefonu: 6147223284
- E-mail: kelsey.troyer@nationwidechildrens.org
Lokalizacje studiów
-
-
Colorado
-
Aurora, Colorado, Stany Zjednoczone, 80045
- Rekrutacyjny
- Children's Hospital Colorado
-
Kontakt:
- Holly Lindsay, MD
- Numer telefonu: 720-777-0461
- E-mail: holly.lindsay@childrenscolorado.org
-
Główny śledczy:
- Holly Lindsay, MD
-
-
District of Columbia
-
Washington D.C., District of Columbia, Stany Zjednoczone, 20010
- Rekrutacyjny
- Children's National Medical Center
-
Kontakt:
- Eugene Hwang, MD
- Numer telefonu: 202-476-5046
- E-mail: ehwang@childrensnational.org
-
Główny śledczy:
- Eugene Hwang
-
-
Florida
-
Miami, Florida, Stany Zjednoczone, 33155
- Rekrutacyjny
- Nicklaus Children's Hospital
-
Kontakt:
- Ziad Khatib, MD
- Numer telefonu: 305-662-8360
- E-mail: ziad.khatib@nicklaushealth.org
-
-
Illinois
-
Chicago, Illinois, Stany Zjednoczone, 60611
- Jeszcze nie rekrutacja
- Ann & Robert H. Lurie Children's Hospital of Chicago
-
Główny śledczy:
- Ashley Plant, MD
-
Kontakt:
- Ashley Plant, MD
- Numer telefonu: 312-227-4090
- E-mail: aplant@luriechildrens.org
-
-
Massachusetts
-
Boston, Massachusetts, Stany Zjednoczone, 02215
- Jeszcze nie rekrutacja
- Dana-Farber Cancer Institute
-
Główny śledczy:
- Karen Wright, MD
-
Kontakt:
- Karen Wright, MD
- Numer telefonu: 617.632.4309
- E-mail: KarenD_wright@dfci.harvard.edu
-
-
Michigan
-
Ann Arbor, Michigan, Stany Zjednoczone, 48109
- Rekrutacyjny
- C.S. Mott Children's Hospital
-
Kontakt:
- John Prensner, MD
- Numer telefonu: 8669094449
- E-mail: prensner@med.umich.edu
-
-
Missouri
-
St Louis, Missouri, Stany Zjednoczone, 63110
- Rekrutacyjny
- St. Louis Children's Hospital
-
Główny śledczy:
- Eric M Thompson, MD
-
Kontakt:
- Eric M Thompson, MD
- E-mail: pedshemonctrialreferral@wustl.edu
-
-
North Carolina
-
Durham, North Carolina, Stany Zjednoczone, 27710
- Rekrutacyjny
- Duke Cancer Center
-
Główny śledczy:
- Daniel Landi, MD
-
Kontakt:
- Daniel Landi, MD
- Numer telefonu: 919-684-5013
- E-mail: pedsneuronc@duke.edu
-
-
Ohio
-
Cincinnati, Ohio, Stany Zjednoczone, 45229
- Rekrutacyjny
- Cincinnati Children's Hospital Medical Center
-
Główny śledczy:
- Peter de Blank, MD
-
Kontakt:
- Peter de Blank, MD
- Numer telefonu: 513-517-2068
- E-mail: Peter.deBlank@cchmc.org
-
Columbus, Ohio, Stany Zjednoczone, 43205
- Rekrutacyjny
- Nationwide Children's Hospital
-
Główny śledczy:
- Maryam Fouladi, MD
-
Kontakt:
- Kennedy Thompson
- Numer telefonu: 614-722-5043
- E-mail: kennedy.thompson@nationwidechildrens.org
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Stany Zjednoczone, 19104
- Jeszcze nie rekrutacja
- Children's Hospital of Philadelphia
-
Kontakt:
- Michael J Fisher, MD
- Numer telefonu: 215-590-5188
- E-mail: fisherm@email.chop.edu
-
Główny śledczy:
- Michael J Fisher, MD
-
-
Texas
-
Houston, Texas, Stany Zjednoczone, 77030
- Rekrutacyjny
- Texas Children's Hospital
-
Kontakt:
- Patricia Baxter, MD
- Numer telefonu: 832-824-4681
- E-mail: pabaxter@txch.org
-
Główny śledczy:
- Patricia Baxter, MD
-
-
Washington
-
Seattle, Washington, Stany Zjednoczone, 98105
- Rekrutacyjny
- Seattle Children's Hospital
-
Kontakt:
- Sarah Leary, MD
- Numer telefonu: 206-987-2106
- E-mail: sarah.leary@seattlechildrens.org
-
Główny śledczy:
- Sarah Leary, MD
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria for patients with recurrent /progressive medulloblastoma (stratum I)
-
Age: Patients must be ≥3 and ≤39 years of age at the time of study enrollment
-
Diagnosis: Patients must have a diagnosis of medulloblastoma that is recurrent, progressive or refractory. All patients must have histological verification of a medulloblastoma, at original diagnosis or relapse.
• Patients must have measurable disease defined as a lesion that can be measured in two perpendicular diameters on MRI.
-
Metastatic Disease: Patients with M+ disease are eligible.
-
Performance Status:
Karnofsky ≥ 50% for patients >16 years of age or Lansky ≥ 50 for patients ≤ 16 years of age. Patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score.
-
Prior Therapy:
-
Radiotherapy: prior radiotherapy requirements Patients must have received prior disease-directed therapy including radiotherapy for their diagnosis of medulloblastoma unless patients are less than 4 years of age at the time of enrollment.
For those less than 4 years of age at the time of enrollment, prior disease directed therapy does not have to include prior radiotherapy.
Patients must have had their last fraction of:
- Craniospinal irradiation, total body irradiation or radiation to ≥ 50% of pelvis > 3 months prior to enrollment.
- Focal irradiation > 4 weeks prior to enrollment
-
Myelosuppressive anticancer therapy: Patients must have received their last dose of myelosuppressive anticancer therapy at least 21 days prior to enrollment
-
Immunotherapy: Patients must have received their last dose of any immunotherapy agents at least 30 days prior to enrollment
-
Non-myelosuppressive anticancer agents: Patients must have received their last dose of non-myelosuppressive anticancer agents at least 7 days prior to study enrollment.
-
Antibodies: Patients must have received their last dose of any antibodies at least 21 days prior to enrollment.
-
Hematopoietic growth factors: Patients must have received their last dose of hematopoietic growth factors at least 14 days prior to enrollment for a long-acting growth factor (e.g. pegfilgrastim) or 7 days prior to enrollment for short-acting growth factor.
-
Autologous stem cell infusion: At least 90 days must have elapsed after an autologous stem cell infusion
-
-
Organ Function Requirements:
-
Adequate bone marrow function defined as:
- ANC (Absolute neutrophil count) ≥ 1000/µl.
- Platelets ≥ 100,000/µl. (may be supported)
- Hemoglobin > 8 g/dL. (may be supported)
-
Adequate Renal Function defined as: Creatinine clearance or radioisotope GFR ≥ 70ml/min/1.73 m2 or A serum creatinine based on age/gender as follows:
Age: Maximum Serum Creatinine (mg/dL)
- 2 to < 6 years: 0.8 (Male) 0.8 (Female)
- 6 to < 10 years: 1 (Male) 1 (Female)
- 10 to < 13 years: 1.2 (Male) 1.2 (Female)
- 13 to < 16 years: 1.5 (Male) 1.4 (Female)
- ≥ 16 years: 1.7 (Male) 1.4 (Female)
-
Adequate Liver Function Defined as
- Total bilirubin ≤1.5 times institutional ULN
- AST(SGOT) ≤3 × institutional upper limit of normal
- ALT(SGPT) ≤3 × institutional upper limit of normal
-
Adequate Neurological Function Defined as
- Patients with neurological deficits should have deficits that are stable for a minimum of 2 weeks prior to enrollment.
- Patients with current seizure disorders may be enrolled if seizures are well- controlled on antiepileptic therapies.
-
Patients of childbearing or child-fathering potential must be willing to use a medically acceptable form of birth control, which includes abstinence, while being treated on this study and for three months after drug cessation.
-
Signed informed consent according to institutional guidelines must be obtained prior to enrollment.
-
Inclusion Criteria for Patients with Newly-Diagnosed High-Grade Gliomas (HGG) (stratum II, CLOSED on 19Aug2026) and Newly-Diagnosed (DIPG) (stratum III)
-
Age: Patients must be ≥3 and ≤39 years of age at the time of study enrollment
-
Diagnosis
-
Stratum II [CLOSED on 19Aug2026]: patients must have histologically confirmed, newly-diagnosed HGG (such as anaplastic astrocytoma, glioblastoma, H3K27-altered DMG).
- Patients with a newly-diagnosed HGG must enroll within 6 weeks of their final dose of standard radiation therapy with or without chemotherapy.
- Patients with primary spinal cord tumors are eligible
-
Stratum III: Patients with a newly-diagnosed DIPG:
- Patients with a radiographically typical DIPG, defined as a tumor with a pontine epicenter and diffuse involvement of more than 2/3 of the pons, are eligible without histologic confirmation.
- Patients with brainstem lesions that do not meet these radiographic criteria will be eligible if there is histologic confirmation of an infiltrating astrocytoma WHO grades II-IV.
-
-
Metastatic Disease: Patients with M+ disease are eligible.
-
Performance Status:
Karnofsky ≥ 50 for patients > 16 years of age and Lansky ≥ 50 for patients ≤ 16 years of age (See Appendix I). Patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score.
-
Prior Therapy requirements: Patients must have received no prior therapy other than surgery, radiation, chemotherapy during radiotherapy and/or steroids (dexamethasone with goal to wean dexamethasone throughout protocol therapy).
Patients with a newly diagnosed high-grade glioma or DIPG must enroll within 6 weeks of their final dose of standard of care radiation therapy with or without chemotherapy.
- Patients with HGG or DIPG are permitted, but not required, to have received chemotherapy during radiation. Bevacizumab is permitted prior to enrollment in patients with DIPG or HGG. Patients must have received their last dose of bevacizumab at least 14 days prior to enrollment.
- For HGG patients, Patients must have received radiotherapy at a standard dose of 54-59.4 Gy in 1.8 Gy fractions for approximately 6 weeks with an acceptable variance of 10%. Radiation therapy must have begun no later than 42 days after the date definitive surgery.
- For patients with DIPG, Patients must have received radiotherapy at a standard dose of radiotherapy of 54 Gy in 1.8 Gy daily fractions for approximately 6 weeks with an acceptable variance rate of 10%. Radiation therapy must have begun no later than 42 days after the date of radiographic diagnosis or biopsy
- For patients with spinal cord HGG: Patients must have received radiotherapy at a standard dose of 45-54 Gy in 1.8 Gy fractions for approximately 6-7 weeks with an acceptable variance of 10%
- For patients with metastatic disease: Patients may have received standard dose CSI
-
Organ Function Requirements:
-
Adequate bone marrow function defined as • ANC (Absolute neutrophil count) ≥ 1000/µl.
• Platelets ≥ 100,000/µl. (may be supported)
• Hemoglobin > 8 g/dL. (may be supported)
-
Adequate Renal Function defined as: Creatinine clearance or radioisotope GFR ≥ 70ml/min/1.73 m2 or A serum creatinine based on age/gender as follows:
Age: Maximum Serum Creatinine (mg/dL)
• 2 to < 6 years: 0.8 (Male) 0.8 (Female)
• 6 to < 10 years: 1 (Male) 1 (Female)
• 10 to < 13 years: 1.2 (Male) 1.2 (Female)
• 13 to < 16 years: 1.5 (Male) 1.4 (Female)
• ≥ 16 years: 1.7 (Male) 1.4 (Female)
-
Adequate Liver Function Defined as:
• Total bilirubin ≤1.5 times institutional ULN
- AST(SGOT) ≤3 × institutional upper limit of normal
- ALT(SGPT) ≤3 × institutional upper limit of normal
-
Adequate Neurological Function Defined as:
-
Patients with neurological deficits should have deficits that are stable for a minimum of 1 week prior to enrollment.
d. Patients of childbearing or child-fathering potential must be willing to use a medically acceptable form of birth control, which includes abstinence, while being treated on this study.
e. Signed informed consent according to institutional guidelines must be obtained prior to registration and for 3 months after drug cessation.
Exclusion Criteria for all strata:
-
Pregnancy or Breast-Feeding:
- Pregnant or breast-feeding women will not be entered on this study due to known or unknown risks of fetal and teratogenic adverse events as seen in animal/human studies. Pregnancy tests must be obtained in girls who are post-monarchal. Males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method.
- Pregnancy Prevention Patients of childbearing or child fathering potential must be willing to use a medically acceptable form of birth control, which includes abstinence, while being treated on this study and for 3 months after drug cessation.
-
Study Specific:
- Active infection requiring treatment
- Patients with malignancy related to HIV or solid organ transplant: known history of HIV, HBV surface antigen positivity or positive HCV antibody are not eligible. Viral testing is not required unless clinically indicated in patients without a known history
- Known immunosuppressive disease
- Patients with active renal, cardiac (congestive cardiac failure, myocardial infarction, myocarditis), or moderate to severe pulmonary problems generally defined by need for medical intervention (e.g., oxygen, medications) and/or limiting activities of daily living (generally CTCAE Grade 2 or higher) or shortness of breath with limited exertion are not eligible. Pulmonary conditions include (but are not limited to) COPD, asthma, and hemi-pneumectomy
- Patients receiving concomitant immunosuppressive agents for medical conditions; inhaled corticosteroids for asthma are allowed.
- Patients receiving concomitant tumor-directed therapy
- Patients receiving any other investigational drug therapy.
- Patients on dexamethasone > 0.1 mg/Kg/day up to maximum dose of 4 mg/day or equivalent.
- Patients with any clinically significant unrelated systemic illness (serious infections or significant cardiac, pulmonary, hepatic or other organ dysfunction).
- Patients with inability to return for follow-up visits or obtain follow-up studies required to assess toxicity to therapy
- Patients at high risk for imminent neurologic decline due to extensive bulk disease, midline shift, or herniation on MRI. These patients should be discussed with the study chairs.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Nie dotyczy
- Model interwencyjny: Zadanie dla jednej grupy
- Maskowanie: Brak (otwarta etykieta)
Liczba ramion
Broń i interwencje
Grupa uczestników / ArmGrupa uczestników / Arm |
Interwencja / LeczenieInterwencja / Leczenie |
|---|---|
|
Eksperymentalny: PEP-CMV
Participants will receive standard chemotherapy with temozolomide for five days, followed by the study vaccine, PEP-CMV, on day 21. Participants will receive a tetanus diphtheria (Td) booster vaccine and a small dose Td preconditioning vaccine to prepare their immune system to receive their first PEP-CMV vaccine. Participants will receive the first 3 PEP-CMV vaccines every 2 weeks, and after the third vaccine, the rest of the vaccines will be given monthly. The first cycle is 77 days and all subsequent cycles are 28 days. The PEP-CMV vaccine may be received for up to 24 cycles. |
The PEP-CMV vaccine will be administered as follows: 250 µg/m2 (up to a maximum of 500 µg) of Component A mixed with Montanide ISA-51 (1:1 volume ratio) intradermally administered half in the RIGHT groin and half in the LEFT groin. Patients will receive one course of temozolomide 200 mg/m2/day x 5 days on Days 1-5 of cycle 1
Inne nazwy:
Patients will receive a tetanus (Td) booster (Td 5 flocculation units, Lf) at the time of enrollment. Immunotherapy begins with a Td pre-conditioning vaccine (Td 1 Lf, in 0.4 mL of saline) delivered i.d. at the RIGHT groin site of the vaccine injection 6-24 hours prior to the first vaccine on day 21.
Inne nazwy:
|
Co mierzy badanie?
Podstawowe miary wyniku
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
4-mo PFS in patients with recurrent medulloblastoma
Ramy czasowe: 4 months
|
To determine the progression-free survival (PFS) at 4 months in pediatric or young adult patients with recurrent medulloblastoma treated with PEP-CMV. |
4 months
|
|
1-yr OS in patients with newly diagnosed DIPG
Ramy czasowe: one year
|
To estimate the 1-year Overall Survival (OS) distribution in patients with newly diagnosed DIPG treated with radiotherapy followed by PEP-CMV |
one year
|
|
1-yr PFS in patients with newly diagnosed HGG
Ramy czasowe: one year
|
To estimate the 1-year Progression Free Survival (PFS) distribution in patients with newly diagnosed HGG treated with radiotherapy followed by PEP-CMV |
one year
|
Miary wyników drugorzędnych
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
ORR in patients with recurrent medulloblastoma
Ramy czasowe: From Day 1 of treatment through 30 days following end of protocol treatment
|
To determine the objective response rate (ORR) = partial response (PR) + complete response (CR) in patients with recurrent medulloblastoma treated with PEP-CMV |
From Day 1 of treatment through 30 days following end of protocol treatment
|
|
PFS in patients with recurrent medulloblastoma
Ramy czasowe: one year
|
To determine the 1-year Progression Free Survival (PFS) in patients with recurrent Medulloblastoma treated with PEP-CMV. |
one year
|
|
OS in patients with newly diagnosed HGG by PEP-CMV
Ramy czasowe: 2 years
|
To determine the 2-year Overall Survival (OS) in patients newly diagnosed with HGG treated with PEP-CMV. |
2 years
|
Współpracownicy i badacze
Sponsor
Sponsor
Współpracownicy
Współpracownicy
Śledczy
Śledczy
- Główny śledczy: Maryam Fouladi, MD, Nationwide Children's Hospital
- Krzesło do nauki: Daniel Landi, MD, Duke Cancer Center
- Krzesło do nauki: Eric M Thompson, MD, Washington University - St. Louis Children's Hospital
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Rozpoczęcie studiów
Zakończenie podstawowe (Szacowany)
Zakończenie podstawowe
Ukończenie studiów (Szacowany)
Ukończenie studiów
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Pierwszy wysłany
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia wysłana aktualizacja
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
- Choroby mózgu
- Choroby ośrodkowego układu nerwowego
- Choroby Układu Nerwowego
- Nowotwory według lokalizacji
- Nowotwory
- Nowotwory według typu histologicznego
- Nowotwory gruczołowe i nabłonkowe
- Nowotwory neuroepitelialne
- Nowotwory neuroektodermalne
- Nowotwory, komórki rozrodcze i embrionalne
- Nowotwory, tkanka nerwowa
- Nowotwory Układu Nerwowego
- Nowotwory neuroektodermalne, prymitywne
- Nowotwory ośrodkowego układu nerwowego
- Nowotwory mózgu
- Nowotwory pnia mózgu
- Nowotwory podnamiotowe
- Rozlany wewnętrzny glejak mostu
- Glejak
- Rdzeniak zarodkowy
- Organiczne chemikalia
- Związki heterocykliczne, 1-ring
- Związki heterocykliczne
- Azole
- Dacarbazine
- Triazennes
- Imidazoles
- Produkty biologiczne
- Złożone mieszanki
- Szczepionki bakteryjne
- Szczepionki
- Toksoid błonicy
- Toksoidy
- Toksoid tężca
- Szczepionki, połączone
- Temozolomid
- Szczepionka szczepionki błonicy-czujnika
Inne numery identyfikacyjne badania
Inne numery identyfikacyjne badania
- CONNECT1906
- R01FD007283 (Dotacja/umowa FDA USA)
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .